TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04267692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HaRTC
Description: HaRT-C participants will attend 8, virtual, adapted, low-barrier, weekly, closed-group Talking Circles-- named Harm Reduction Treatment Circles or HaRTC -- lasting approximately 2 hours each. During the HaRTC, the circle keeper will present the day's harm reduction topic, smudge the space, and allow participants to open themselves up to the circle. Topics presented by the Circle Keeper focus on harm-reduction and improving overall quality of health. Abstinence from alcohol use is not a requirement. We will not limit participants' access to treatment or services in either arm.
Study: NCT04422730

Intervention type: BEHAVIORAL
Intervention: Psychological evaluation
Description: Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups

Intervention type: BEHAVIORAL
Intervention: Psychological evaluation
Description: Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups

Intervention type: BEHAVIORAL
Intervention: Psychological evaluation
Description: Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups

Intervention type: BEHAVIORAL
Intervention: Psychological evaluation
Description: Patients will be answer to validated test about how they feel. Psychological interview is also possible depending on patients availability. The different answers will be compared between the four groups
Study: NCT02955940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 5 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the same dose provided in the parent study at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the same dose provided in the parent study at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib at the same dose provided in the parent study at the time of the rollover.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib at the same dose provided in the parent study at the time of the rollover.
Study: NCT01663662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolvaptan
Study: NCT03492775

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine belongs formally to the alkylators, but has been shown to have a unique mechanism of action. The dose limiting toxicity of bendamustine is its reversible suppression of bone marrow function with drops in leukocyte and thromobocyte counts.
Study: NCT01616134

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Korea red ginseng
Description: Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
Study: NCT02280473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Refresh Optive® Gel Drops
Description: Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: REFRESH LIQUIGEL®
Description: REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
Study: NCT03268473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Experimental: Non-surgical periodontal therapy in patient with OSAS and Periodontitis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control: Non-surgical periodontal therapy in Periodontitis
Study: NCT04706416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl glucosamine (NAG)
Description: Patients with novel coronavirus (COVID-19) will be treated with N-acetylglucosamine (NAG) (700 mg every 12 hours) as first-line treatment for 30 days, along with standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients do not receive treatment with N-Acetylglucosamine. They may receive other treatments at the discretion of the treating physician, as with the treatment group.
Study: NCT00749554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disc biacuplasty
Description: The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham biacuplasty
Description: Probes not inserted into disc, no RF electricity applied.
Study: NCT04496310

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedicine versus usual care (face to face visit)
Study: NCT00976573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study: NCT04409119

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LV pacing
Description: LV lead in a CS branch
Study: NCT03596983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention
Description: * Sleep Diaries (Daily)~* Fitbit 24/7~* Phone/ video conference calls (weekly with study team)~* Epworth Sleepiness Scale (weekly)~* PROMIS fatigue scale-evening (weekly)
Study: NCT01884285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C1: Abiraterone acetate combination with AZD8186
Description: Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
Study: NCT02514980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infraorbital nerve block using bupivacaine 0.25% on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Infraorbital nerve block using bupivacaine 0.25% on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Infraorbital nerve block using 0.5mg/kg ketamine on each side.
Study: NCT01884285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D1: AZD2014 combination with AZD8186
Description: Dose \& schedule finding of AZD8186 in combination with AZD2014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part D2 AZD2014 combination with AZD8186
Description: Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C2: Abiraterone acetate combination with AZD8186
Description: Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
Study: NCT01320579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-UCA 2.5% emulsion cream
Description: 2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cis-UCA 5% emulsion cream
Description: 5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for cis-UCA emulsion cream
Description: The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protopic® 0.1% ointment
Description: 0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
Study: NCT00844298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib+mVPD
Description: 1. Induction:~   * Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)~  * Vincristine 2 mg iv push (d1, 8, 15, 22)~  * Prednisolone 60 mg/m2/day po (d1-28)~  * Nilotinib 400mg bid/d (d8-)~2. Consolidation A (cycle1)~   * Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)~  * Vincristine 2 mg iv (d1, 8)~  * Prednisolone 60 mg/m2/day po (d1-14)~  * Nilotinib 400mg bid/d~3. Consolidation B (cycles 2\&4)~   * Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)~  * Etoposide 150 mg/m2/day iv over 3 hours (d1-4)~  * Nilotinib 400mg bid/d~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)~  * Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,~  * Nilotinib 400mg bid/d~5. Maintenance~   ◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)~6. Consider alloHCT
Study: NCT03867708

Intervention type: RADIATION
Intervention: ASD device closure
Description: transcatheter secundum ASD device closure

Intervention type: RADIATION
Intervention: ASD device closure
Description: transcatheter secundum ASD device closure
Study: NCT02157415

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uro-Tainer Polihexanide 0.02%
Description: Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
Study: NCT01663662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04171115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G03-52-01
Description: G03-52-01 administered intramuscularly
Study: NCT04372693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: impliminting Online Distance Learning
Description: as a result of (COVID-19) social distancing measures, the Online Distance Learning will be implemented without prior planning for undergraduate nursing students
Study: NCT00445055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Droperidol
Description: Intravenous injection
Study: NCT04171115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered intramuscularly
Study: NCT02550275

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological test
Study: NCT04388358

Intervention type: DRUG
Group type: OTHER
Intervention: Shin-yi-san + Xiao-qing-long-tang + Xiang-sha-liu-jun-zi-tang by the weight of 9g+3g+3g/day
Description: All patients were treated with mixed formula of Chinese medicine for one month
Study: NCT02677558

Intervention type: OTHER
Intervention: Transthoracic Echocardiography
Description: Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.

Intervention type: OTHER
Intervention: Transthoracic Echocardiography
Description: Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
Study: NCT00680940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel & Cisplatin
Description: Chemotherapeutic agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mycobacterium w.
Description: Immunomodulator
Study: NCT03960801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil group
Description: bolus intravenous injection of 3 to 4µg/kg of remifentanil after hypnotic administration for a crush anesthetic induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular blockade group
Description: Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
Study: NCT02997891

Intervention type: DIAGNOSTIC_TEST
Intervention: everyday activity
Description: To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).

Intervention type: DIAGNOSTIC_TEST
Intervention: everyday activity
Description: To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).

Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive performance
Description: Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.

Intervention type: DIAGNOSTIC_TEST
Intervention: cognitive performance
Description: Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
Study: NCT05311072

Intervention type: PROCEDURE
Intervention: pulmonary endarterectomy or balloon pulmonary angioplasty
Description: A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.

Intervention type: PROCEDURE
Intervention: pulmonary endarterectomy or balloon pulmonary angioplasty
Description: A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.

Intervention type: PROCEDURE
Intervention: pulmonary endarterectomy or balloon pulmonary angioplasty
Description: A multidisciplinary team make the final treatments for patients with CTEPH depending on their disease and preferences.
Study: NCT00820885

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
Study: NCT00820885

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
Study: NCT02550275

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological test

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Study: NCT02682563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg QD
Description: Dapagliflozin 10mg once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 30mg QD
Description: Gliclazide30mg once daily for 12 weeks
Study: NCT02710006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonohysterography
Description: Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
Study: NCT03523871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavyret
Description: Patients will be on 8 weeks of Mavyret
Study: NCT04558099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: Described previously
Study: NCT00820885

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
Study: NCT00816140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cravit based triple therapy
Description: Levofloxacin based triple therapy~LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klaricid based triple therapy
Description: Clarithromycin based triple therapy~CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days
Study: NCT00820885

Intervention type: DRUG
Group type: OTHER
Intervention: teduglutide
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.

Intervention type: DRUG
Group type: OTHER
Intervention: tedguglutide
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
Study: NCT02754089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhus Coriaria L.(Rhus)
Description: 500 mg twice daily after meals for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily after meals for 6 weeks
Study: NCT03273751

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
Study: NCT02739724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adnexal surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adnexal surgery
Study: NCT02831920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CEUS and targeted biopsies
Study: NCT03135548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab (low dose)
Description: 12 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab (high dose)
Description: 12 weeks treatment